According to Medscape, research presented at the 2007 Gastrointestinal Cancer Symposium in Orlando, Florida, determined that when Avastin (bevacizumab) was added to the chemotherapy regimen of people with metastatic colon cancer, their tumors took longer to progress. Specifically, those receiving standard chemotherapy remained progression-free for an average of eight months. Those who received Avastin in addition to standard chemo remained progression-free for an average of nine-and-a-half months.
This Week in Research (January 26, 2007)
by Donna Myers
for About.comUpdated: April 15, 2007
About.com Health's Disease and Condition content is reviewed by the Medical Review Board
Explore Colon Cancer
Must Reads
About.com Special Features
Learn how you can reduce your your numbers with these nutrition and exercise tips. More >
Keep yourself, and your family, happy and healthy this fall with these tips. More >
Also from About.com:
©2009 About.com, a part of The New York Times Company.
All rights reserved.